Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Warrick Dunnm who played 12 seasons in the NFL as a running back for the Tampa Bay Buccaneers and Atlanta Falcons, has been supporting single-parent families since his 1997 rookie season, when he started the Homes for the Holidays program to provide economically-disadvantaged single parents and their children with comprehensive programming for first-time homeownership. In September 2018, the former NFL player’s charitable efforts, as well as a few facts about his upbringing and the death of his mother, were boiled down into a meme spread via social media:  This meme, for the most part, provided accurate information about Warrick Dunn and his charitable efforts. Dunn’s mother, Betty Dunn Smothers, was a police officer in Baton Rouge who was killed in 1993 while working a second job as a security guard:  Corporal Betty Smothers was shot and killed in an ambush attack while moonlighting as a security guard. Corporal Smothers was in uniform and driving a marked patrol car when she and the store manager went to a bank to make a night deposit. As they sat in the patrol car, three suspects approached and opened fire. They fatally wounded Corporal Smothers and injured the manager. All three suspects were arrested after the incident and sentenced to death for Corporal Smothers’ murder. Corporal Smothers had been employed with the Baton Rouge City Police Department for 14 years, and is survived by her two daughters and four sons. Smothers’ passing came just a few days before Dunn’s 18th birthday and a month before he committed to playing college football at Florida State University (FSU). He was the eldest of Smothers’ children, and by most accounts he assumed a father-figure role in the life of his five younger siblings. Here’s how the Los Angeles Times described Dunn and his siblings in a December 1994 article headlined “Turning His Grief to Good: Florida State Running Back Warrick Dunn Sets an Example for All”:  Derek is doing well at Catholic High. Travis is fast and Bryson small, but he’s growing. Summer and Samantha are running track and doing well in school. You listen to Warrick Dunn and hear a proud father talking of his children. And then you realize that Dunn is only 19. Still, he’s in charge of his brothers and sisters, ages 11-17, now that Betty is gone. She was his best friend, a mother who worked two jobs, 16 hours a day, to keep the family together and to provide a few of the things that make being a kid a little more fun. If there’s anything harder than a teen-ager being asked to go to the hospital in a police car, identify his mother and then go home to tell his brothers and sisters what happened, he doesn’t want to know about it. It was Dunn, handling things as he always had, the father figure, but now without a mother. “I never really had a childhood,” he says. “I’ve never been able to go out and just go crazy, like most kids, because I grew up staying in the house a lot, baby-sitting.”  Dunn graduated from FSU and was selected in the first round of the 1997 NFL draft by the Tampa Bay Buccaneers. The rookie running back was challenged by head coach Tony Dungy to give back to the community during his time in Florida, and so Dunn decided to start the “Homes for the Holidays” program in order to help provide homes to single-parent families in honor of his late mother. The program managed to house three families during its first year. By 2018, that number had grown to 159:  “My rookie year in the NFL, in Tampa, I was challenged by coach [Tony] Dungy,” Dunn said. He told us, ‘If you are going to live in this community, you want to be a part of this community and give back.’ From that challenge, I thought about my mom and her dream of home ownership, and that’s how it all started. We did three homes in 1997, and now we’re up to 159. “I grew up in a situation where we needed a lot of support. I lost my mom at 18. Single mom, six kids, and a Baton Rouge police officer. She was gunned down by armed robbers at a bank. When she lost her life, the city of Baton Rouge started a fund for us. And that’s how we were able to survive and pay bills. And when I saw that from the city, that really helped me understand what it means to care about your neighbor and to give back and support. I just think now I have been driven for so many years—this is part of who I am, to want to see people smile and help anyone that I can possibly help.” Our only quibble with this meme is the statement that Dunn “built and paid for over 145 houses for single mothers.” While the former NFL quarterback has certainly donated plenty of time, money, and effort into his charitable endeavors, he did not single-handedly build and pay for all these homes. Dunn’s non-profit, Warrick Dunn Charities, partners with other non-profits such as Habitat for Humanity to build homes for disadvantaged families: Even in retirement, Dunn and his Warrick Dunn Charities are still partnering with Habitat for Humanity to build homes for disadvantaged families across the United States. In December, Dunn and Habitat combined to build homes number 158 (in Detroit) and 159 (in Atlanta) and place two families in them before the holidays. Furnished, as Dunn like to say, “all the way down to the toothbrushes in the bathroom.” Dunn’s charity provides a down payment for the home, completely furnishes it, and provides other services such as financial literacy program in order to assist single parents as they become first time homeowners: Warrick Dunn Charities was created from the belief that a better future starts with hope. We are dedicated to strengthening and transforming communities by combating poverty, hunger and improving the quality of life for families and children. We help families thrive academically, socially, and economically. Warrick Dunn Charities, a 501(c)(3) recognized nonprofit, has helped single parents and children thrive academically, socially and economically. Warrick Dunn Charities has awarded millions in home furnishings, food and other donations to single-parent families and children across the nation to combat poverty, hunger and ensure families have comfortable surroundings and basic necessities to improve their quality of life. This meme’s popularity in September 2018 was likely connected to a controversy surrounding another former NFL player: Colin Kaepernick. A number of social media users shared this meme along with messages stating that Nike should have used Dunn, not Kaepernick, in their latest commercial:  This meme misleadingly suggests that Colin Kaepernick has not similarly sacrificed by using his own money for charitable endeavors. However, in January 2018 Kaepernick completed his pledge to donate a total of $1 million to charity over eighteen months, with a list of all the organizations he donated to  viewable here. And Dunn himself praised Nike’s latest advertising campaign for raising Kaepernick’s profile as the latter drove the conversation about social justice: “I think it’s a brilliant campaign,” Dunn said. “They just raised his profile because Kaepernick the last couple of years has been the face of this movement of social justice.” “To be the first guy to come out and really talk about the issues that black kids, black men are being shot and killed, I commend him,” Dunn said in a CNN interview. When asked if he thought Nike’s stance to create the campaign was a financial or moral decision, Dunn cited the latter. “It’s a moral decision. It can’t be about finances,” Dunn said.

Ex Output:
Warrick Dunn started a charitable program to house single-parent families in honor of his mother, a police officer who was killed when he was a teenager.


Ex Input:
The question of cost is cited in the final line of the story, which suggests that the scoring system can “address escalating health care cost issues.” But we didn’t think that was specific enough to warrant a Satisfactory score. The story doesn’t clue readers in to the fact that the financial burden can be measured in billions of dollars — a single screening test recommended for millions of Americans can cost thousands of dollars apiece. The other cost issue specific to this test is that it takes valuable time for providers to retrieve a reputable risk calculator when sitting with a patient and enter in the specific data points, including in this case waist circumference, which clinicians often do not measure as a ‘vital sign’ per se. The story cites a study that credits colonoscopy with reducing the risk of death from colon cancer by about 50 percent, by removing polyps. It would have been helpful for the story to explain what that relative reduction in risk means in absolute terms (e.g. did the rate of cancer death go from 50% to 25% or from 2% to around 1%?) The story also notes that the study found that patients with a low to intermediate risk score “still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.” We’ll give credit here for the story’s provision of these key statistics, which do give a sense as how well the test accurately identifies truly low-risk individuals. However, we’d note that the benefit here should ideally refer to the ability of the algorithm to classify people at all risk levels (including high-risk), and therefore target the highest-risk patients for colonoscopy. The story doesn’t really get into discussion of the predictive power of the test, referred to as a likelihood ratio, which is in the study manuscript. However, this is a difficult concept for most health care providers and patients, and we think it’s understandable that the story did not include a full discussion of this topic. The harm of a screening test such as this really is “getting it wrong” in terms of predicting someone to be at low risk and finding them to have a higher risk polyp or malignancy. As noted above, the story cautions that “low- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.” This story accurately explains that the research was about predictive modeling, and explains the components of the risk score as well as the study design. There are some cautionary notes in the text, including a statement from outside expert that “the data from this study is not strong enough to spur any changes in current screening recommendations,” an opinion shared by an editorialist on the study. We think this is sufficient for a Satisfactory rating. The story does not hype the incidence or seriousness of the disease. The prevalence statistics cited are consistent with these National Cancer Institute figures. The story contains two independent voices. The perspective they provide is a particular strength of the article. We wish that more stories would reach out to experts not affiliated with the studies being reported on for context. The story notes that a variety of screening tests exist, but the relevant alternative here is actually other risk calculators, which the authors of the study describe and cite but are not routinely used. The story doesn’t mention these other calculators and why they are seldom used — context that would have deepened reader understanding of the issue. Although availability isn’t explicitly addressed, this risk calculator is now available (implicitly) by virtue of publication of the paper. It is a simple scoring system that can be implemented based on the information in the paper, and the story makes this clear. We’ll rate this Satisfactory. The story makes it sound as if this is a first-of-its-kind tool. However, risk calculation tools for colon cancer have been in circulation for many years. We could not find a news release related to this study. But in any case, the comments from two independent experts assure us that the story wasn’t based on a news release.

Ex Output:
'Scoring System' May Spot Those in Greatest Need of Colonoscopy; But one expert cautions that even 'low risk' patients can still develop suspicious polyps


Ex Input:
"Highly anticipated data for a Gilead Sciences Inc (GILD.O) experimental antiviral drug are expected later this month. Analysts are also awaiting results in the near-term for products already approved for other conditions from companies such as Roche Holding (ROG.S) and Regeneron Pharmaceuticals (REGN.O). While experts estimate an approved vaccine could be at least a year away, progress toward treatments that benefit some COVID-19 patients could help investors gauge when the epidemic could come under control and some economic activity might  resume. “The more we see positive clinical data, the more investors will be comforted in the fact that this is a transitory issue like all epidemics are,” said Art Hogan, chief market strategist at National Securities. Early signs of a slowdown in hospitalizations and intensive care needs in coronavirus hotspots in the United States and abroad have fed a stock market turnaround sparked by massive support from the Federal Reserve and a more than $2 trillion government bailout. As of Monday, the S&P 500 .SPX was off about 21% from its Feb. 19 all-time high but had rebounded 19% since March 23. “With each incremental piece of good news, that gets us closer to the end of the epidemic and the economic damage that falls in its wake,” Hogan said. New York is nearing a plateau in the number of coronavirus patients hospitalized, Governor Andrew Cuomo said on Tuesday, even though the number of the deaths in the state hit a single-day high. Governments around the world have locked down their communities - urging citizens to stay inside and ordering restaurants, stores and other businesses shuttered - to contain the spread of COVID-19 cases, which have exceeded 1.4 million globally with over 80,000 deaths, according to a Johns Hopkins tally. Drugmakers are studying ways to combat the respiratory illness, for which there are no approved treatments, as hospitals face strains from the flood of patients. More than 330 clinical studies related to COVID-19 are listed in clinicaltrials.gov, a database maintained by the U.S. National Institutes of Health, including many seeking to test drugs already approved for other conditions. Gilead's remdesivir, which is administered intravenously, is one experimental treatment that has captured investors' attention. The biotechnology company's chief executive on March 28 said initial data would arrive in the ""coming weeks"" here and analysts said data could come in mid April. Remdesivir previously failed as a treatment for the Ebola virus. But it helped prevent disease and reduce severity of symptoms in monkeys infected with a virus more closely related to the new coronavirus in a study, raising hopes. Some analysts are cautioning against expecting that remdesivir will show an overwhelming benefit. Initial data are expected to come from studies of patients with relatively severe COVID-19. Because antivirals work best when patients are healthier, those results may show limited effectiveness, said Evan Seigerman, a biotech analyst at Credit Suisse. Even if remdesivir proves effective, the amount of the drug that would be available remains a concern. Gilead said last weekend here its existing supply could equate to more than 140,000 courses of treatment. Data is also anticipated for Regeneron (REGN.O) and Sanofi’s (SASY.PA) Kevzara, perhaps by the end of the month, and for Roche’s (ROG.S) Actemra - two similar rheumatoid arthritis drugs being tested for COVID-19 illness. Studies are also ongoing for hydroxychloroquine, a decades-old malaria drug that has been used by doctors for COVID-19 despite controversy over its effectiveness. “Just knowing that something works means investors can start thinking about the other side of this,” said Keith Lerner, chief market strategist at Truist/SunTrust Advisory Services, in emailed comments to Reuters, “both from a human side and an economic and market perspective.”"

Ex Output:

Investors await data on coronavirus drugs as market rally builds.